Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-17
2007-04-17
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S206000, C544S207000, C544S218000
Reexamination Certificate
active
10622721
ABSTRACT:
The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.
REFERENCES:
patent: 2002/0016825 (2002-02-01), Falotico et al.
patent: WO 96/32907 (1996-10-01), None
patent: WO 01/25220 (2001-04-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Shapiro, Clinical Cancer Research 10: 4270-4275, 2004.
Davis et al., “Prevention of Chemotherapy-induced Alopecia in Rats by CDK Inhibitors”, Science, vol. 291, pp. 134-137 (2001).
International Search Report dated Dec. 5, 2003 for related International Application No. PCT/US03/22390.
DeAngelis Alan
Emanuel Stuart L.
Kuo Gee-Hong
Middleton Steve
Wang Aihua
Balasubramanian Venkataraman
Donnelly Laura
Janssen Pharmaceutica N.V.
LandOfFree
Substituted triazine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted triazine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted triazine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3726208